An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice.
In the present study, we have investigated the efficacy of Indian ayurvedic herbal formulation Triphala on monosodium urate crystal-induced inflammation in mice; an experimental model for gouty arthritis and compared it with that of the non-steroidal anti-inflammatory drug, Indomethacin. The anti-arthritic effect of Triphala was evaluated by measuring changes in the paw volume, lysosomal enzyme activities, lipid peroxidation, anti-oxidant status and inflammatory mediator TNF-alpha in control and monosodium urate crystal-induced mice. The levels of beta-glucuronidase and lactate dehydrogenase were also measured in monosodium urate crystal-incubated polymorphonuclear leucocytes (PMNL). Triphala treatment (1 gm/kg/b.w. orally) significantly inhibited the paw volume and the levels of lysosomal enzymes, lipid peroxidation and inflammatory mediator tumour necrosis factor-alpha; however the anti-oxidant status was found to be increased in plasma, liver and spleen of monosodium urate crystal-induced mice when compared to control mice. In addition, beta-glucuronidase and lactate dehydrogenase level were reduced in Triphala (100 microg/ml) treated monosodium urate crystal-incubated polymorphonuclear leucocytes. In conclusion, the results obtained clearly indicated that Triphala exerted a strong anti-inflammatory effect against gouty arthritis.
Sabina
E P
EP
School of Bio-engineering and Biosciences, VIT University, Vellore-632 014, Tamil Nadu, India.
Rasool
M
M
D000118:Acetylglucosaminidase / Q000097:blood / Q000378:metabolism; D000135:Acid Phosphatase / Q000097:blood / Q000378:metabolism; D000284:Administration, Oral; D000818:Animals; D016512:Ankle Injuries / Q000139:chemically induced / Q000188:drug therapy; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism; D001169:Arthritis, Experimental / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D015210:Arthritis, Gouty / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005966:Glucuronidase / Q000097:blood / Q000378:metabolism; D007213:Indomethacin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007271:Injections, Intradermal; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008054:Lipid Peroxides / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008247:Lysosomes / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D009504:Neutrophils / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D010936:Plant Extracts / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011208:Powders; D013154:Spleen / Q000187:drug effects / Q000201:enzymology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014527:Uric Acid / Q000008:administration & dosage / Q000633:toxicity; D001616:beta-Galactosidase / Q000097:blood / Q000378:metabolism
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D008054:Lipid Peroxides; D010936:Plant Extracts; D011208:Powders; D014409:Tumor Necrosis Factor-alpha; C520904:triphala; D014527:Uric Acid; D007770:L-Lactate Dehydrogenase; D000135:Acid Phosphatase; D001616:beta-Galactosidase; D005966:Glucuronidase; D000118:Acetylglucosaminidase; D007213:Indomethacin